

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED



Inventor Application of:
William Shive
Flora H. Pettit

Serial No.: 10/010,716

Filed: October 26, 2001

For: METHODS FOR DETERMINING
TOXICITY REVERSING AGENTS

Group Art Unit: 1623

APR 10 2002

Examiner: Unknown TECH CENTER 1600/2900

Atty. Dkt. No.: UTSB:705US/DLP

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

March 26, 2002

Date

Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10103590/DLP.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 26, 2002

1623



FULBRIGHT & JAWORSKI L.L.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

RECEIVED

APR 10 2002

TECH CENTER 1600/2900

FILE: UTSB:705US

March 26, 2002

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

APR 25 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 26, 2002	
Date	Priya D. Subramony

Commissioner for Patents
Washington, DC 20231

RE: SN 10/010,716 "METHODS FOR DETERMINING TOXICITY REVERSING AGENTS"
- William Shive and Flora H. Pettit

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (A1, B1, C1-C5).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10103590/DLP.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cmb
Encl: as noted